Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Capital Group American Mutual Comp

American Funds American Mutual A

SGI Global Equity I

Causeway Simulated Intl Val ADR Model

Russell Personalized Core Equity SMA

SGI Enhanced Global Income ETF

Capital Group American Mutual Trust U0

SGI Global Equity

Russell Personalized 70/30 Core Alloc

Catalyst/MAP Global Equity A

Arrowstreet Intl Eq ACWI ex US CIT M

VALMXVL B1

First Trust Value Line® Dividend ETF

VanEck Pharmaceutical ETF

Mondrian Int Eq Delivered Strategy

MAP Global Equity Composite

MAP Global Balanced Composite

ActivePassive International Equity ETF

MAP Global Equity Ex-Options Composite

Avantis International Equity ETF

Capital Research Global Investors

Morgan Stanley - Brokerage Accounts

Van Eck Associates Corporation

Northern Trust Corp

Managed Asset Portfolios, LLC

Envestnet Asset Management Inc

BlackRock Inc

Causeway Capital Management LLC

Wells Fargo & Co

Bank of America Corp

Jane Street Group LLC

Federated Hermes Inc

Mondrian Investment Partners Ltd

Arrowstreet Capital Limited Partnership

Goldman Sachs Group Inc

Millennium Management LLC

Brandes Investment Partners & Co

Renaissance Technologies Corp

First Trust Advisors L.P.

FMR Inc

Takeda Pharmaceutical Co Ltd ADR

Mr. Christophe  Weber

President, CEO & Representative Director

Dr. Seigo  Izumo

Chair of Management Board

Mr. Milano  Furuta

CFO & Director

Mr. Haruhiko  Hirate

Member of Management Board

Mr. Salvatore  Alesci M.D., Ph.D.

Member of Management Board and Head of R&D Global Science & Biomedical Policy

Norimasa  Takeda

Chief Accounting Officer & Corporate Controller

Mr. Iwaaki  Taniguchi

Senior Vice President of Corporate Finance & Controlling Department

Mr. Gabriele  Ricci

Chief Data & Technology Officer

Mr. Christopher David  O'Reilly

Global Head of Investor Relations & Global Finance

Mr. Yoshihiro  Nakagawa

Global General Counsel

TAK's next earnings is on January 30, 2025 (Before Market Open)

TAK's latest dividend is 0.29221 USD on March 27, 2024

Takeda Pharmaceutical Co Ltd ADR (TAK) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Takeda Pharmaceutical Co Ltd ADR (TAK) Earnings Report Date and History | NYSE

TAK's next earnings is on January 30, 2025 (Before Market Open)

When is the earnings report for TAK?

TAK Earnings History

TAK's latest dividend is 0.29221 USD on March 27, 2024

TAK Stock Discussion Forum and Message Board

News for NYSE: TAK